Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy worldwide, still representing an important cause of cancer-related death. Over the next few years, novel systemic treatment options have emerged. Among these, immune checkpoint inhibitors (ICIs) have been widely eval...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, Giorgio Frega, Andrea Palloni, Simona Tavolari, Giovanni Brandi
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2021-12-01
Edice:	Frontiers in Oncology
Témata:	hepatocellular carcinoma HCC immunotherapy biomarkers PD-L1
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2021.803133/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!